#4506
Matching adjusted indirect comparison (MAIC) of [177Lu]Lu-DOTA-TATE (177Lu-DOTATATE) vs. streptozocin-based chemotherapies (STZ-BC) as first-line (1L) treatment for advanced grade 2/3 (G2/G3) pancreatic NETs (pNETs)
Introduction:
The NETTER-2 trial showed improved progression-free survival (PFS) with 1L 177Lu-DOTATATE vs. high dose octreotide in advanced G2/G3 pNETs. No published evidence exists comparing 177Lu-DOTATATE with other recommended 1L treatments, such as STZ-BC, hence indirect comparisons need to be conducted.
Conference:
Presenting Author:
Navalkissoor S
Authors:
Navalkissoor S,
Capdevila J,
Deshayes E,
Gerard L,
Srirajaskanthan R,
Keywords:
pancreatic neuroendocrine tumour,
[177lu]lu-dotatate,
streptozocin,
5-fluorouracil,
matching adjusted indirect comparison,
#3120
Thinking and confusion about a well-differentiated grade 3 pancreatic neuroendocrine tumor
Introduction:
In WHO Classification of Digestive System Tumors (2019 edition), pancreatic NENs are divided into well-differentiated NETs (including G1, G2, G3) and poorly differentiated NECs mainly based on the mitoses and Ki-67. G3 pNET and pNEC should have more than 20 mitoses/10 HPFs or their Ki-67 should be higher than 20%. However, WHO didn't clearly distinguish the Ki-67 cut-off value between them, and only 55% was recommended.
Conference:
18th Annual ENETS Concerence (2021)
Presenting Author:
Ma Y
Authors:
Ma Y,
Song L,
Li X,
Yang M,
Wang F,
Keywords:
pancreatic neuroendocrine carcinoma,
pancreatic neuroendocrine tumor,
G3,
P53,
ATRX,
DAXX,
MEN1,
